

CITATION REPORT

List of articles citing

Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits

DOI: 10.1016/j.yjmcc.2006.10.015

Journal of Molecular and Cellular Cardiology, 2007, 42, 453-8.

Source: <https://exaly.com/paper-pdf/41977175/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
108	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. 2008 , 294, H1398-406		129
107	Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse. <i>Journal of Molecular and Cellular Cardiology</i> , 2007 , 43, 545-51	5.8	16
106	Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. 2007 , 150, 538-40		22
105	Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. 2007 , 152, 855-69		129
104	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. 2007 , 52, 990-1005		45
103	Penile rehabilitation should become the norm for radical prostatectomy patients. 2007 , 4, 538-543		86
102	Signaling pathways in ischemic preconditioning. 2007 , 12, 181-8		253
101	Nonurologic applications of phosphodiesterase type 5 inhibitors. 2007 , 4, 64-70		1
100	Sildenafil citrate concentrations not affecting oxidative phosphorylation depress H ₂ O ₂ generation by rat heart mitochondria. 2008 , 309, 77-85		41
99	Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG. 2008 , 154, 25-31		19
98	Mechanisms of the relaxant effect of vardenafil in rat penile arteries. 2008 , 586, 283-7		18
97	The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. 2008 , 5, 1126-1136		106
96	Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A _{2b} agonists by protein kinase C. 2008 , 295, H1288-H1295		43
95	Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4. 2008 , 102, 966-74		113
94	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. 2008 , 294, H1398-H1406		90
93	Endothelial dysfunction in the mesenteric artery and disturbed nonadrenergic noncholinergic relaxation of the ileum due to intestinal ischemia-reperfusion can be prevented by sildenafil. 2009 , 84, 61-7		6
92	NO- and haem-independent soluble guanylate cyclase activators. 2009 , 309-39		108

91	Cardiovascular effects of phosphodiesterase type 5 inhibitors. 2009 , 6, 658-74	38
90	Mitochondrial involvement in cardiac apoptosis during ischemia and reperfusion: can we close the box?. 2009 , 9, 211-27	35
89	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. 2009 , 30, 1-24	45
88	Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat. 2009 , 108, 755-66	39
87	Regulation and pharmacology of the mitochondrial permeability transition pore. 2009 , 83, 213-25	177
86	Sildenafil augments early protective transcriptional changes after ischemia in mouse myocardium. 2009 , 430, 30-7	6
85	cGMP: Generators, Effectors and Therapeutic Implications. 2009 ,	13
84	Sildenafil increases the force of right atrial contractions in vitro via the NO-guanylyl cyclase pathway involving β adrenoceptor linked mechanisms. 2009 , 61, 1146-52	3
83	Vardenafil reduces testicular damage following ischemia/reperfusion injury in rats. 2009 , 25, 374-80	41
82	BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. 2009 , 30, 1607-13	40
81	Phosphodiesterase 5 inhibitors: are they cardioprotective?. 2009 , 83, 204-12	29
80	Phosphodiesterase-5 inhibitors: future perspectives. 2009 , 15, 3540-51	33
79	Current state of penile rehabilitation after radical prostatectomy. 2010 , 20, 234-40	14
78	Sildenafil citrate augments myocardial protection in heart transplantation. 2010 , 89, 169-77	16
77	Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. 2010 , 105, 155-67	59
76	Erectile function rehabilitation in the radical prostatectomy patient. 2010 , 7, 1687-98	85
75	The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP. 2010 , 107, 1164-6	13
74	Cardioprotective PKG-independent NO signaling at reperfusion. 2010 , 299, H2028-36	38

73	Phospholemmann Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury. 2010 , 299, H827-36	35
72	Penile rehabilitation after prostate cancer treatment: outcomes and practical algorithm. 2011 , 38, 105-18	19
71	Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. 2011 , 93-133	45
70	Effect of apelin-apelin receptor system in postischaemic myocardial protection: a pharmacological postconditioning tool?. 2011 , 14, 909-22	20
69	Phosphodiesterases and cardiac cGMP: evolving roles and controversies. 2011 , 32, 360-5	73
68	Comparative effects of verapamil, nicardipine, and nitroglycerin on myocardial ischemia/reperfusion injury. 2011 , 2011, 521084	11
67	Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. 2011 , 300, H2308-15	56
66	Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. 2011 , 300, H2272-9	58
65	Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. 2012 , 302, H1347-54	55
64	Is inhibition of phosphodiesterase type 5 by sildenafil a promising therapy for volume-overload heart failure?. 2012 , 125, 1341-3	7
63	Endothelial dysfunction in the human umbilical artery due to preeclampsia can be prevented by sildenafil. 2012 , 34, 79-85	12
62	Effect of Sildenafil on Heart Nitric Oxide Metabolism and Mitochondrial Function. 2012 , 169-188	
61	Sildenafil attenuates TNBS-induced colitis in rats: possible involvement of cGMP and KATP channels. 2012 , 26, 190-3	8
60	Effects of sildenafil and/or muscle derived stem cells on myocardial infarction. 2012 , 10, 159	13
59	Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. 2012 , 59, 1921-7	58
58	Discovery of 6-[4-(6-nitroxyhexanoyl)piperazin-1-yl]-9H-purine, as pharmacological post-conditioning agent. 2012 , 20, 5948-56	5
57	Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. 2012 , 7, e45243	65
56	Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. 2012 , 30, 326-35	52

55	Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil. 2013 , 379, 43-9	10
54	Ovariectomy reinstates the infarct size-limiting effect of postconditioning in female rabbits. 2013 , 65, 373-80	5
53	Erectile dysfunction as a cardiovascular risk factor in patients with diabetes. 2013 , 43, 285-92	29
52	PDE5 inhibition against acute renal ischemia reperfusion injury in rats: does vardenafil offer protection?. 2013 , 31, 597-602	12
51	Activation of the homeostatic intracellular repair response during cardiac surgery. 2013 , 216, 719-26; discussion 726-9	32
50	Protective effect of sildenafil on liver injury induced by intestinal ischemia/reperfusion. 2013 , 48, 1707-15	19
49	Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. 2013 , 60, 80-8	62
48	Modulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates sildenafil protection against chemical hypoxia caused by malonate. 2013 , 168, 1820-34	15
47	Adverse impact of diet-induced hypercholesterolemia on cardiovascular tissue homeostasis in a rabbit model: time-dependent changes in cardiac parameters. 2013 , 14, 19086-108	12
46	Balance of nitric oxide and reactive oxygen species in myocardial reperfusion injury and protection. 2013 , 62, 567-75	20
45	Cardioprotective effects of sour cherry seed extract (SCSE) on the hypercholesterolemic rabbit heart. 2013 , 19, 6896-905	28
44	Novel approaches and opportunities for cardioprotective signaling through 3'Scyclic guanosine monophosphate manipulation. 2014 , 19, 269-82	16
43	Tadalafil prevents acute heart failure with reduced ejection fraction in mice. 2014 , 28, 493-500	18
42	Sildenafil citrate in a donation after circulatory death experimental model of renal ischemia-reperfusion injury. 2014 , 98, 612-7	6
41	Diabetic Cardiomyopathy. 2014 ,	2
40	The effects of sildenafil and n-acetylcysteine on ischemia and reperfusion injury in gastrocnemius muscle and femoral artery endothelium. 2015 , 23, 21-30	9
39	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. 2015 , 147, 12-21	144
38	The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism. 2015 , 172, 1996-2009	62

37	PDE5 inhibitors protect against post-infarction heart failure. 2016 , 21, 1194-210	13
36	Drug therapy for erectile dysfunction. 2016 , 172-193	
35	Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. 2016 , 102, 1750-1756	58
34	Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy. 2016 , 39, 1238-52	31
33	Nitric oxide treatments as adjuncts to reperfusion in acute myocardial infarction: a systematic review of experimental and clinical studies. 2016 , 111, 23	45
32	Berbamine postconditioning protects the heart from ischemia/reperfusion injury through modulation of autophagy. 2017 , 8, e2577	52
31	Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors. 2017 , 17, 445-461	7
30	cGMP-Elevating Compounds and Ischemic Conditioning Provide Cardioprotection Against Ischemia and Reperfusion Injury via Cardiomyocyte-Specific BK Channels. 2017 , 136, 2337-2355	92
29	The GTN patch: a simple and effective new approach to cardioprotection?. 2018 , 113, 20	15
28	Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase. 2018 , 114, 822-829	30
27	Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. 2018 , 175, 223-231	21
26	Connexins and Nitric Oxide Inside and Outside Mitochondria: Significance for Cardiac Protection and Adaptation. 2018 , 9, 479	8
25	Renoprotective effect of local sildenafil administration in renal ischaemia-reperfusion injury: A randomised controlled canine study. 2019 , 17, 150-159	8
24	Thyroid hormone postconditioning protects hearts from ischemia/reperfusion through reinforcing mitophagy. 2019 , 118, 109220	13
23	Ischemia Reperfusion Injury: Mechanisms of Damage/Protection and Novel Strategies for Cardiac Recovery/Regeneration. 2019 , 20,	33
22	Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies. 2019 , 20,	88
21	Experimental study on prophylactic effects of vardenafil in ischemia-reperfusion model with intestinal volvulus injury in rats. 2019 , 54, 2172-2177	2
20	Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. 2019 , 73, 195-205	3

19	Nitroglycerine limits infarct size through S-nitrosation of cyclophilin D: a novel mechanism for an old drug. 2019 , 115, 625-636	22
18	N-Acetylcysteine potentiates the haemodynamic-improving effect of sildenafil in a rabbit model of acute pulmonary thromboembolism via the p38 MAPK pathway. 2019 , 46, 163-172	8
17	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. 2020 , 177, 5467-5488	34
16	Icariin attenuates isoproterenol-induced cardiac toxicity in Wistar rats via modulating cGMP level and NF- κ B signaling cascade. 2020 , 39, 117-126	7
15	Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure. 2020 , 34, 401-417	7
14	The Effect of Sildenafil on Selenite-Induced Cataract in Rats. 2020 , 45, 1082-1088	
13	An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases. 2021 , 16, 183-196	3
12	The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure. 2021 , 212, 113123	4
11	Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imaging. 2013 , 8, e83910	29
10	Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor. 2009 , 15, 5091-6	11
9	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. 2021 , 1	1
8	Erectile Function Preservation and Rehabilitation. 2009 , 139-162	
7	Erectile Function Preservation for Men with Cancer. 2011 , 657-673	
6	PDE-5 Inhibitors in Protection of Diabetic Heart. 2014 , 323-338	
5	Non-classical effects of sildenafil in clinical medicine: an interdisciplinary approach. <i>Meditinskiy Sovet</i> , 2019 , 192-202	0.4
4	Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. <i>Experimental and Clinical Cardiology</i> , 2011 , 16, e30-5	39
3	New Possibilities in Heart Failure: The Effects of Tadalafil on Diastolic Function in Patients Undergoing Robot-Assisted Radical Prostatectomy. <i>Applied Sciences (Switzerland)</i> , 2022 , 12, 5629	2.6
2	Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. 2023 , 63,	1

1 Sildenafil affects the human Kir2.1 and Kir2.2 channels at clinically relevant concentrations:
Inhibition potentiated by low Ba²⁺. 14,

1